540 related articles for article (PubMed ID: 8610234)
1. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
2. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
3. Update: vinorelbine (navelbine) in non-small cell lung cancer.
Crawford J
Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
5. Overview of economic analysis of Le Chevalier Vinorelbine Study.
Hillner BE; Smith TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):14-6; discussion 17. PubMed ID: 9556778
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
Coltman CA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
Crawford J
Semin Oncol; 1994 Oct; 21(5 Suppl 10):85-8. PubMed ID: 7526468
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.
Viallet J; Ayoub J; Rousseau P; Souhami L; Hohneker J; Shepherd F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):64-71; discussion 71-2. PubMed ID: 7973771
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
13. Current management of unresectable non-small cell lung cancer.
Livingston RB
Semin Oncol; 1994 Oct; 21(5 Suppl 10):4-11; discussion 11-3. PubMed ID: 7973768
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.
Chang AY; DeVore R; Johnson D
Semin Oncol; 1996 Apr; 23(2 Suppl 5):19-21. PubMed ID: 8610231
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
[TBL] [Abstract][Full Text] [Related]
18. Single-agent vinorelbine in the treatment of non-small cell lung cancer.
Wozniak AJ
Semin Oncol; 1999 Oct; 26(5 Suppl 16):62-6; discussion 71-2. PubMed ID: 10585010
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
